These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1250 related articles for article (PubMed ID: 25860354)
41. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome. Orbach R; Gurevich M; Achiron A Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323 [TBL] [Abstract][Full Text] [Related]
43. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782 [TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis. Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545 [TBL] [Abstract][Full Text] [Related]
45. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Møller HJ; Grønbaek H; Schiødt FV; Holland-Fischer P; Schilsky M; Munoz S; Hassanein T; Lee WM; J Hepatol; 2007 Nov; 47(5):671-6. PubMed ID: 17629586 [TBL] [Abstract][Full Text] [Related]
46. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. Lindén M; Khademi M; Lima Bomfim I; Piehl F; Jagodic M; Kockum I; Olsson T Mult Scler; 2013 Jun; 19(7):863-70. PubMed ID: 23175382 [TBL] [Abstract][Full Text] [Related]
47. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function. Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389 [TBL] [Abstract][Full Text] [Related]
48. Serum markers of macrophage activation in pre-eclampsia: no predictive value of soluble CD163 and neopterin. Kronborg CS; Knudsen UB; Moestrup SK; Allen J; Vittinghus E; Møller HJ Acta Obstet Gynecol Scand; 2007; 86(9):1041-6. PubMed ID: 17712642 [TBL] [Abstract][Full Text] [Related]
49. Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis. Liu Y; Li M; Zhang H; Yin Z; Wang X Lupus; 2024 Oct; 33(12):1279-1288. PubMed ID: 39172599 [TBL] [Abstract][Full Text] [Related]
50. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093 [TBL] [Abstract][Full Text] [Related]
51. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375 [TBL] [Abstract][Full Text] [Related]
53. Macrophage-derived soluble CD163 level in young patients with Gaucher disease: relation to phenotypes, disease severity and complications. Adly AAM; Ismail EAR; Ibraheem TM Int Immunopharmacol; 2015 Feb; 24(2):416-422. PubMed ID: 25587690 [TBL] [Abstract][Full Text] [Related]
54. Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis. Agah E; Zardoui A; Saghazadeh A; Ahmadi M; Tafakhori A; Rezaei N PLoS One; 2018; 13(1):e0190252. PubMed ID: 29346446 [TBL] [Abstract][Full Text] [Related]
55. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients. Tanimura H; Mizuno K; Okamoto H Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688 [TBL] [Abstract][Full Text] [Related]
56. Increased serum levels of macrophage activation marker sCD163 in Dengue patients. S S SG; Pillai AB; Ramachandrappa VS; T K; Dhodapkar R; Kah J; Rajendiran S J Clin Virol; 2017 Jan; 86():62-67. PubMed ID: 27960133 [TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342 [TBL] [Abstract][Full Text] [Related]
58. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412 [TBL] [Abstract][Full Text] [Related]
59. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. Martin SJ; McGlasson S; Hunt D; Overell J J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141 [TBL] [Abstract][Full Text] [Related]
60. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]